Published in Haematologica on February 14, 2015
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | NCT01037556
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood (2015) 1.52
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol (2016) 0.84
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res (2015) 0.81
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br J Cancer (2016) 0.79
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biol Ther (2015) 0.79
DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chem Res Toxicol (2016) 0.77
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia (2016) 0.76
Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model. Cancer Sci (2016) 0.76
Hypoxia and Hypoxia-Inducible Factors in Leukemias. Front Oncol (2016) 0.76
The hypoxia signalling pathway in haematological malignancies. Oncotarget (2017) 0.75
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy. Clin Cancer Res (2017) 0.75
Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome. Int J Mol Sci (2017) 0.75
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol (2010) 2.63
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 2.35
Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol (2013) 2.27
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A (2009) 1.95
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res (2007) 1.60
Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res (2010) 1.56
Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc (2002) 1.47
Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol (2005) 1.42
Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics (2008) 1.24
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One (2011) 1.23
Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood (2013) 1.09
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol (2009) 1.03
Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia (2004) 1.01
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol (2010) 0.94
Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res (2012) 0.93
Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood (2014) 0.91
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer (2011) 0.90
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol (2014) 0.90
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. Front Oncol (2013) 0.86
Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy. J Pharmacol Exp Ther (2011) 0.86
Gastrointestinal manifestations of leukemia. J Gastroenterol Hepatol (2012) 0.82
Neutropenic enterocolitis: current issues in diagnosis and management. Curr Infect Dis Rep (2007) 0.81
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol (2015) 2.42
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol (2015) 1.61
Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis. Ann Surg Oncol (2016) 1.44
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood (2005) 0.93
Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol (2014) 0.88
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica (2016) 0.84
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica (2016) 0.84
Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leuk Res (2013) 0.83
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol (2016) 0.83
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res (2014) 0.81
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol (2015) 0.80
Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget (2015) 0.79
Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding. Clin Trials (2014) 0.79
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica (2015) 0.79
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res (2015) 0.79
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol (2015) 0.78
Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol (2015) 0.78
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol (2015) 0.78
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget (2016) 0.78
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol (2016) 0.77
Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. Oncotarget (2016) 0.77
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol (2015) 0.76
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica (2016) 0.75
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet (2015) 0.75
Targeting acute myeloid leukemia with TP53-independent vosaroxin. Future Oncol (2016) 0.75
The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed (2015) 0.75
Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget (2017) 0.75
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia (2020) 0.75
Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype. Eur J Haematol (2017) 0.75
Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. Ther Adv Hematol (2019) 0.75
Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. Mod Pathol (2021) 0.75
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma (2022) 0.75
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol (2017) 0.75
Adult cancer-related hemophagocytic lymphohistiocytosis - a challenging diagnosis: a case report. J Med Case Rep (2017) 0.75
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol (2017) 0.75